Abstract
The term ‘breast cancer’ describes a heterogeneous collection of neoplasms arising from the mammary epithelium. Tumors in different patients display diverse morphologies, molecular phenotypes, responses to therapy, probabilities of relapse and overall survival. Current histopathological classification systems aim to categorise tumors into subgroups to inform patient management decisions, but the diversity within subgroups is considerable. Molecular analyses such as gene expression profiling, and more recently, massively parallel sequencing technologies, have been employed to increase the degree of resolution in breast cancer taxonomies. It will take time for this information to be translated into the clinic. Sequencing projects have also been instrumental in revealing the true extent of intratumoral heterogeneity: three-dimensional variability in the genetic, phenotypic, cellular and microenvironmental constitution of individual tumors. This variability underlies clinical problems such as metastasis and drug resistance, and will present additional challenges as breast cancer diagnostics evolves to include higher resolution molecular analyses. Intratumoral heterogeneity will need to be carefully considered as we move towards more personalized models of breast cancer patient management.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ, (eds) (2012) WHO Classification of Tumors of the Breast. Int Agency for Res on Cancer (IARC), Lyon
Raffan E, Semple RK (2011) Next generation sequencing–implications for clinical practice. Br Med Bull 99:53–71. doi:10.1093/029
Radovich M (2012) Next-generation sequencing in breast cancer: translational Sci and clinical integration. Pharmacogenomics 13(6):637–639. doi:10.2217/12.18
Swanton C, Burrell RA, Futreal PA (2011) Breast cancer genome heterogeneity: a challenge to personalized medicine? Breast Cancer Res 13(1):104. doi:10.1186/bcr2807
Ellis IO, Schnitt SJ, Sastre-Garau X (2003) Invasive breast carcinomas. In: Tavassoli FA, Devilee P (eds) WHO classification of tumors pathology and genetics of tumors of the breast and female genital organs. IARC Press, Lyon
Boyd W (1934) A textbook of pathology: an introduction to medicine, 2nd edn. Henry Kimpton, London
Pinder SE (2010) Ductal carcinoma in situ (DCIS): Pathological features, differential diagnosis, prognostic factors and specimen evaluation. Modern pathol: an official J US Can Acad Pathol 23(Suppl 2):S8–13. doi:10.1038/2010.40
Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LF et al (2008) Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 216(2):141–150. doi:10.1002/2407
Rakha EA, Ellis IO (2010) Lobular breast carcinoma and its variants. Semin Diagn Pathol 27(1):49–61
Tognon C, Knezevich SR, Huntsman D, Roskelley CD, Melnyk N, Mathers JA et al (2002) Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2(5):367–376 S1535610802001800[pii]
Persson M, Andren Y, Mark J, Horlings HM, Persson F, Stenman G (2009) Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci USA 106(44):18740–18744. doi:10.1073/0909114106
Keller PJ, Arendt LM, Skibinski A, Logvinenko T, Klebba I, Dong S et al (2012) Defining the cellular precursors to human breast cancer. Proc Natl Acad Sci USA 109(8):2772–2777. doi:10.1073/1017626108
Elston CW, Ellis IO, Pinder SE (1998) Prognostic factors in invasive carcinoma of the breast. Clin Oncol 10(1):14–17
Pereira H, Pinder SE, Sibbering DM, Galea MH, Elston CW, Blamey RW et al (1995) Pathological prognostic factors in breast cancer. IV: should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. Histopathol 27(3):219–226
Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathol 19(5):403–410
Aleskandarany MA, Green AR, Benhasouna AA, Barros FF, Neal K, Reis-Filho JS et al (2012) Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. Breast Cancer Res 14(1):R3. doi:10.1186/3084
Rakha EA, El-Sayed ME, Lee AH, Elston CW, Grainge MJ, Hodi Z et al (2008) Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Oncol: Official J Am Soc Clin Oncol 26(19):3153–3158. doi:10.1200/2007.15.5986
Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V et al (2010) Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res 12(4):207. doi:10.1186/2607
Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J et al (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98(4):262–272. doi:10.1093/jnci/052
Galea MH, Blamey RW, Elston CE, Ellis IO (1992) The nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat 22(3):207–219
Sundquist M, Thorstenson S, Brudin L, Nordenskjold B (1999) Applying the nottingham prognostic index to a Swedish breast cancer population. South East Swedish breast cancer study group. Breast Cancer Res Treat 53(1):1–8
Mook S, Schmidt MK, Rutgers EJ, van de Velde AO, Visser O, Rutgers SM et al (2009) Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: A hospital-based retrospective cohort study. Lancet Oncol 10(11):1070–1076. doi: S1470-2045(09)70254-2 [pii] 10.1016/S1470-2045(09)70254-2
Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B (2009) Senn HJ (2009) Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer. Ann Oncol: J ESMO 20(8):1319–1329. doi:10.1093
Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351(9114):1451–1467
Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP et al (1992) Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest oncology group study. J Oncol: Official J Am Soc Clin Oncol 10(8):1284–1291
Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ et al (2007) American Society of Clinical Oncology/College of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131(1):18–43. doi:10.1043/1543-2165131
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–182
Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL (1989) HER-2/neu oncogene protein and prognosis in breast cancer. J Oncol: Official J Am Soc Clin Oncol 7(8):1120–1128
Chia S, Norris B, Speers C, Cheang M, Gilks B, Gown AM et al (2008) Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Oncol: Official J Am Soc Clin Oncol 26(35):5697–5704. doi:10.1200/2007.15.8659
Madarnas Y, Trudeau M, Franek JA, McCready D, Pritchard KI, Messersmith H (2008) Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review. Cancer Treat Rev 34(6):539–557. doi:10.1016/2008.03.013
Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res: An Official J Am Assoc Cancer Res 13(15):4429–4434. doi:10.1158/1078-0432
Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V et al (2011) Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Modern pathol: An Official J US Can Acad Pathol 24(2):157–167. doi:10.1038/2010.200
Hammond ME, Hayes DF, Wolff AC, Mangu PB, Temin S (2010) American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract 6(4):195–197. doi:10.1200/JOP.777003
Seol H, Lee HJ, Choi Y, Lee HE, Kim YJ, Kim JH et al (2012) Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Mod pathol: An Official J US Can Acad Pathol. doi:10.1038/2012.36
Vance GH, Barry TS, Bloom KJ, Fitzgibbons PL, Hicks DG, Jenkins RB et al (2009) Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med 133(4):611–612. doi:10.1043/1543-2165-133.4.611
Geyer FC, Weigelt B, Natrajan R, Lambros MB, de Biase D, Vatcheva R et al (2010) Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J Pathol 220(5):562–573. doi:10.1002/2675
Korkola JE, DeVries S, Fridlyand J, Hwang ES, Estep AL, Chen YY et al (2003) Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res 63(21):7167–7175
Weigelt B, Geyer FC, Natrajan R, Lopez-Garcia MA, Ahmad AS, Savage K et al (2010) The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type. J Pathol 220(1):45–57. doi:10.1002/2629
van ‘t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530–536
Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F et al (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365(9460):671–679. doi:10.1016/S0140-6736(05)17947-1
Ma XJ, Hilsenbeck SG, Wang W, Ding L, Sgroi DC, Bender RA et al (2006) The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Oncol: Official J Am Soc Clin Oncol 24(28):4611–4619. doi:10.1200/2006.06.6944
Goetz MP, Suman VJ, Ingle JN, Nibbe AM, Visscher DW, Reynolds CA et al (2006) A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin Cancer Res: An Official J Am Assoc Cancer Res 12(7):2080–2087. doi:10.1158/1078-0432.CCR-05-1263
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al (2000) Molecular portraits of human breast tumors. Nature 406(6797):747–752. doi:10.1038/35021093
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869–10874. doi:10.1073/pnas.19136709898/19/10869
Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF et al (2006) The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7:96. doi:1471-2164-7-9610.1186
Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A et al (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100(18):10393–10398
Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T et al (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Oncol 27(8):1160–1167. doi:JCO.2008.18.137010.1200/JCO.2008.18.1370
Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100(14):8418–8423
Harrell JC, Prat A, Parker JS, Fan C, He X, Carey L et al (2011) Genomic analysis identifies unique sigNats predictive of brain, lung, and liver relapse. Breast Cancer Res Treat. doi:10.1007/s10549-011-1619-7
Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH et al (2010) Metastatic behavior of breast cancer subtypes. J Oncol: Official J Am Soc Clin Oncol 28(20):3271–3277. doi:10.1200/JCO.2009.25.9820
Korde LA, Lusa L, McShane L, Lebowitz PF, Lukes L, Camphausen K et al (2010) Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer. Breast Cancer Res Treat 119(3):685–699. doi:10.1007/s10549-009-0651-3
Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11(16):5678–5685
Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B et al (2008) Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis sigNats. Breast Cancer Res 10(4):R65. doi:212410.1186/2124
Kwei KA, Kung Y, Salari K, Holcomb IN, Pollack JR (2010) Genomic instability in breast cancer: pathogenesis and clinical implications. Mol Oncol 4(3):255–266. doi:10.1016/2010.04.001
Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D et al (2007) BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 26(14):2126–2132. doi:1210014/10.1038/1210014
Liu X, Holstege H, van der Gulden H, Treur-Mulder M, Zevenhoven J, Velds A et al (2007) Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci USA 104(29):12111–12116. doi:10.1073/0702969104
McCarthy A, Savage K, Gabriel A, Naceur C, Reis-Filho JS, Ashworth A (2007) A mouse model of basal-like breast carcinoma with metaplastic elements. J Pathol 211(4):389–398. doi:10.1002/2124
Proia TA, Keller PJ, Gupta PB, Klebba I, Jones AD, Sedic M et al (2011) Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. Cell Stem Cell 8(2):149–163. doi:10.1016/2010.12.007
Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK et al (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14(5):1368–1376. doi:14/5/1368/10.1158/1078-0432.CCR-07-1658
Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10(16):5367–5374. doi:10.1158/1078-0432.CCR-04-022010/16/5367
Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S et al (2012) Dissecting the heterogeneity of triple-negative breast cancer. J Col Official J Am Soc Clin Oncol 30(15):1879–1887. doi:10.1200/JCO.2011.38.2010
Fulford LG, Easton DF, Reis-Filho JS, Sofronis A, Gillett CE, Lakhani SR et al (2006) Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathol 49(1):22–34. doi:HIS2453/10.1111/j.1365-2559.2006.02453.x
Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT et al (2006) Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 19(2):264–271. doi: 3800528 [pii] 10.1038/modpathol.3800528
Banerjee S, Reis-Filho JS, Ashley S, Steele D, Ashworth A, Lakhani SR et al (2006) Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol 59(7):729–735. doi:10.1136/2005.033043
Bergamaschi A, Kim YH, Wang P, Sorlie T, Hernandez-Boussard T, Lonning PE et al (2006) Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 45(11):1033–1040. doi:10.1002/20366
Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL et al (2006) Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10(6):529–541. doi:10.1016/2006.10.009
Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y et al (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. doi:10.1038/10933
Fulford LG, Reis-Filho JS, Ryder K, Jones C, Gillett CE, Hanby A et al (2007) Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res 9(1):R4. doi:10.1186/1636
Liu S, Lachapelle J, Leung S, Gao D, Foulkes WD, Nielsen TO (2012) CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res 14(2):R48. doi:10.1186/3148
Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L et al (2011) A clinically relevant gene sigNat in triple negative and basal-like breast cancer. Breast Cancer Res 13(5):R97. doi:10.1186/3035
Guedj M, Marisa L, de Reynies A, Orsetti B, Schiappa R, Bibeau F et al (2011) A refined molecular taxonomy of breast cancer. Oncogene. doi:10.1038/2011.301
Peppercorn J, Perou CM, Carey LA (2008) Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest 26(1):1–10. doi:789315352/10.1080/07357900701784238
Weigelt B, Geyer FC, Reis-Filho JS (2010) Histological types of breast cancer: how special are they? Mol Oncol 4(3):192–208. doi:10.1016/2010.04.004
Rakha EA, Aleskandarany M, El-Sayed ME, Blamey RW, Elston CW, Ellis IO et al (2009) The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast. Eur J Cancer 45(10):1780–1787. doi:10.1016/2009.02.014
Weigelt B, Kreike B, Reis-Filho JS (2009) Metaplastic breast carcinomas are basal-like breast cancers: A genomic profiling analysis. Breast Cancer Res Treat 117(2):273–280. doi:10.1007/s10549-008-0197-9
Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ et al (2012) The genomic and transcriptomic architecture of 2,000 breast tumors reveals novel subgroups. Nature. doi:10.1038/10983
Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D et al (2005) Identification of molecular apocrine breast tumors by microarray analysis. Oncogene 24(29):4660–4671. doi:10.1038/1208561
Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS et al (2009) Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69(10):4116–4124. doi:0008-5472.CAN-08-344110.1158/0008-5472
Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z et al (2007) Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8(5):R76. doi:10.1186
Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI et al (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12(5):R68. doi:10.1186/2635
Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C et al (2006) An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25(28):3994–4008. doi:10.1038/1209415
Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A et al (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 106(33):13820–13825. doi:10.1073/0905718106
Ni M, Chen Y, Lim E, Wimberly H, Bailey ST, Imai Y et al (2011) Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 20(1):119–131. doi:10.1016/2011.05.026
van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW et al (2002) A gene-expression sigNat as a predictor of survival in breast cancer. N Engl J Med 347(25):1999–2009 doi:10.1056/021967
Buyse M, Loi S, van’t Veer L, Viale G, Delorenzi M, Glas AM et al (2006) Validation and clinical utility of a 70-gene prognostic sigNat for women with node-negative breast cancer. J Natl Cancer Inst 98(17):1183–1192. doi: 10.109398/17/1183/329
Bueno-de-Mesquita JM, Linn SC, Keijzer R, Wesseling J, Nuyten DS, van Krimpen C et al (2009) Validation of 70-gene prognosis sigNat in node-negative breast cancer. Breast Cancer Res Treat 117(3):483–495. doi:10.1007/s10549-008-0191-2
Cardoso F, Van’t Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ (2008) Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol: Official J Am Soc Clin Oncol 26(5):729–735. doi:10.1200/2007.14.3222
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826. doi:10.1056/041588
Paik S (2007) Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncol 12(6):631–635. doi:10.1634/12-6-631
Goldstein LJ, Gray R, Badve S, Childs BH, Yoshizawa C, Rowley S et al (2008) Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol: Official J Am Soc Clin Oncol 26(25):4063–4071. doi:10.1200/2007.14.4501
EBCTCG (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717. doi:10.1016/S0140-6736(05)66544-0
Cummings MC, Chambers R, Simpson PT, Lakhani SR (2011) Molecular classification of breast cancer: is it time to pack up our microscopes? Pathology 43(1):1–8. doi:10.1097/0b013e328341e0b5
Weigelt B, Baehner FL, Reis-Filho JS (2010) The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol 220(2):263–280. doi:10.1002/2648
Weigelt B, Pusztai L, Ashworth A, Reis-Filho JS (2012) Challenges translating breast cancer gene sigNats into the clinic. Nat Rev Clin Oncol 9(1):58–64. doi:10.1038/2011.125
Pusztai L, Mazouni C, Anderson K, Wu Y, Symmans WF (2006) Molecular classification of breast cancer: limitations and potential. Oncology 11(8):868–877. doi:10.1634/11/8/868
Weigelt B, Mackay A, A’Hern R, Natrajan R, Tan DS, Dowsett M et al (2010) Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol 11(4):339–349. doi:10.1016/S1470-2045(10)70008-5
Shendure J (2008) The beginning of the end for microarrays? Nat Meth 5(7):585–587. doi:10.1038/0708-585
Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ et al (2012) The genomic and transcriptomic architecture of 2,000 breast tumors reveals novel subgroups. Nature. doi:10.1038/10983
Wang Z, Gerstein M, Snyder M (2009) RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 10(1):57–63. doi:10.1038/2484
Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW et al (2010) Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464(7291):999–1005. doi:10.1038/08989
Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A et al (2009) Mutational evolution in a lobular breast tumor profiled at single nucleotide resolution. Nature 461(7265):809–813. doi:10.1038/08489
Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC et al (2012) The landscape of cancer genes and mutational processes in breast cancer. Nature. doi:10.1038/11017
Evans JP, Meslin EM, Marteau TM, Caulfield T (2011) Genomics. Deflating the genomic bubble. Science 331(6019):861–862. doi:10.1126/Sci.1198039
Aparicio SA, Huntsman DG (2010) Does massively parallel DNA resequencing signify the end of histopathology as we know it? J Pathol 220(2):307–315. doi:10.1002/2636
Dennis C (2012) Mouse ‘avatars’ could aid pancreatic cancer therapy. Nat News. doi:10.1038/2012.10259
Clarke CL, Sandle J, Jones AA, Sofronis A, Patani NR, Lakhani SR (2006) Mapping loss of heterozygosity in normal human breast cells from BRCA1/2 carriers. Br J Cancer 95(4):515–519. doi:10.1038/sj.bjc.6603298
Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B et al (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467(7319):1114–1117. doi:10.1038/09515
Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366(10):883–892. doi:10.1056/1113205
Smallwood JA, Morgan GR, Cooper A, Kirkham N, Williams CJ, Whitehouse JM et al (1984) Correlations between clonogenicity and prognostic factors in human breast cancer. Br J Surg 71(2):109–111
Moezzi J, Ali-Osman F, Nicholson GL, Ungerleider JS, Murphy MJ Jr (1986) Relationship between histopathology and in vitro clonogenicity in breast cancer. Breast Cancer Res Treat 8(2):147–156
Grimshaw MJ, Cooper L, Papazisis K, Coleman JA, Bohnenkamp HR, Chiapero-Stanke L et al (2008) Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells. Breast Cancer Res 10(3):R52. doi:10.1186/2106
Nio Y, Tamura K, Kan N, Inamoto T, Ohgaki K, Kodama H (2000) Anticancer chemosensitivity profiles of human breast cancer cells assessed by in vitro DNA synthesis inhibition assay. Anticancer Res 20(2B):1237–1244
Greaves M, Maley CC (2012) Clonal evolution in cancer. Nature 481(7381):306–313. doi:10.1038/10762
Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194(4260):23–28
Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J et al (2011) Tumor evolution inferred by single-cell sequencing. Nature 472(7341):90–94. doi:10.1038/09807
Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ et al (2011) Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144(1):27–40. doi:10.1016/j.cell.2010.11.055
Marusyk A, Almendro V, Polyak K (2012) Intratumor heterogeneity: a looking glass for cancer? Nat Rev Cancer 12(5):323–334. doi:10.1038/3261
Marusyk A, Polyak K (2010) Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 1:105–117. doi:10.1016/2009.11.002
Hanahan D, Weinberg Robert A (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. doi:10.1016/j.cell.2011.02.013
Anderson K, Lutz C, van Delft FW, Bateman CM, Guo Y, Colman SM et al (2011) Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469(7330):356–361. doi:10.1038/09650
Ruiz C, Lenkiewicz E, Evers L, Holley T, Robeson A, Kiefer J et al (2011) Advancing a clinically relevant perspective of the clonal Nat of cancer. Proc Natl Acad Sci U S A 108(29):12054–12059. doi:10.1073/pnas.1104009108
Carter H, Chen S, Isik L, Tyekucheva S, Velculescu VE, Kinzler KW et al (2009) Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res 69(16):6660–6667. doi:10.1158/0008-5472
Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ et al (2007) The genomic landscapes of human breast and colorectal cancers. Science 318(5853):1108–1113. doi:10.1126/1145720
Torkamani A, Schork NJ (2008) Prediction of cancer driver mutations in protein kinases. Cancer Res 68(6):1675–1682. doi:10.1158/0008-5472
Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO et al (2011) Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci USA 108(19):7950–7955. doi:10.1073/1102454108
Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH et al (2009) Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15(8):907–913. doi:10.1038/2000
Visvader JE (2011) Cells of origin in cancer. Nature 469(7330):314–322. doi:10.1038/09781
Clevers H (2011) The cancer stem cell: premises, promises and challenges. Nat Med 17(3):313–319. doi:10.1038/2304
Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, Natrajan R et al (2010) BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 7(3):403–417. doi:10.1016/2010.07.010
Rosen JM, Jordan CT (2009) The increasing complexity of the cancer stem cell paradigm. Science 324(5935):1670–1673. doi:10.1126/1171837
Eldar A, Elowitz MB (2010) Functional roles for noise in genetic circuits. Nature 467(7312):167–173. doi:10.1038/09326
Korkaya H, Liu S, Wicha MS (2011) Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest 121(10):3804–3809. doi:10.1172/57099
Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H et al (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14(5):518–527. doi:10.1038/1764
Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H et al (2004) Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 6(1):17–32. doi:10.1016/2004.06.010
Ma XJ, Dahiya S, Richardson E, Erlander M, Sgroi DC (2009) Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res 11(1):R7. doi:10.1186/2222
Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH et al (2011) Tumor-infiltrating CD8 + lymphocytes predict clinical outcome in breast cancer. J Clin Oncol: Official J Am Soc Clin Oncol 29(15):1949–1955. doi:10.1200/2010.30.5037
Ladoire S, Arnould L, Apetoh L, Coudert B, Martin F, Chauffert B et al (2008) Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3 + regulatory T cells. Clinical Cancer Res: An Official J Am Assoc Cancer Res 14(8):2413–2420. doi:10.1158/1078-0432
Taskar KS, Rudraraju V, Mittapalli RK, Samala R, Thorsheim HR, Lockman J et al (2011) Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm Res. doi:10.1007/s11095-011-0601-8
Lin NU, Dieras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ et al (2009) Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15(4):1452–1459. doi:10.1158/1078-0432.CCR-08-1080
Weigelt B, Glas AM, Wessels LF, Witteveen AT, Peterse JL, van’t Veer LJ (2003) Gene expression profiles of primary breast tumors maintained in distant metastases. Proc Natl Acad Sci USA 100(26):15901–15905. doi:10.1073/26340671002634067100
Klein CA (2009) Parallel progression of primary tumors and metastases. Nat Rev Cancer 9(4):302–312. doi:10.1038/2627
Da Silva L, Simpson PT, Smart CE, Cocciardi S, Waddell N, Lane A et al (2010) HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Res 12(4):R46. doi:10.1186/2603
Wu JM, Fackler MJ, Halushka MK, Molavi DW, Taylor ME, Teo WW et al (2008) Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res: An Official J Am Assoc Cancer Res 14(7):1938–1946. doi:10.1158/1078-0432.CCR-07-4082
Arslan C, Sari E, Aksoy S, Altundag K (2011) Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature. Expert Opin Ther Targets 15(1):21–30. doi:10.1517/14656566.2011.537260
St Romain P, Madan R, Tawfik OW, Damjanov I, Fan F (2012) Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or fiction? A clinicopathologic analysis. Hum Pathol 43(3):398–404. doi:10.1016/2011.05.009
Houssami N, Macaskill P, Balleine RL, Bilous M, Pegram MD (2011) HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis. Breast Cancer Res Treat 129(3):659–674. doi:10.1007/s105490111632
Wu JM, Halushka MK, Argani P (2010) Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancer. Hum Pathol 41(6):914–917. doi:10.1016/2009.10.022
Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C et al (2012) Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol: Official J Am Soc Clin Oncol 30(6):587–592. doi:10.1200/2010.33.5232
Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS et al (2012) Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481(7382):506–510. doi:10.1038/10738
Gerlinger M, Swanton C (2010) How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer 103(8):1139–1143. doi:10.1038/sj.bjc.6605912
Turner NC, Reis-Filho JS (2012) Genetic heterogeneity and cancer drug resistance. Lancet Oncol 13(4):e178–e185. doi:10.1016/s1470-2045(11)70335-7
Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C (2012) Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 4(127):127ps110. doi:10.1126/3003854
MammaPrint by Agendia. http://www.agendia.com/pages/mammaprint/21.php. Accessed May 2012
Oncotype DX breast cancer assay. http://www.oncotypedx.com/. Accessed May 2012
Von Hoff DD, Stephenson JJ Jr, Rosen P, Loesch DM, Borad MJ, Anthony S et al (2010) Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory cancers. J Clinical Oncol: Official J Am Soc Clin Oncol 28(33):4877–4883. doi:10.1200/2009.26.5983
Caris Target Now Molecular Profiling by Caris Life Scis. http://www.carislifeScis.com/oncology-target-now. Accessed May 2012
Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C et al (2007) Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol: Official J Am Soc Clin Oncol 25(10):1239–1246. doi:10.1200/JCO.2006.07.1522
Toussaint J, Sieuwerts AM, Haibe-Kains B, Desmedt C, Rouas G, Harris AL et al (2009) Improvement of the clinical applicability of the genomic grade index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues. BMC Genomics 10:424. doi:10.1186/1471216410424
MapQuant Dx by Ipsogen. http://www.ipsogen.com. Accessed May 2012
Ma XJ, Salunga R, Dahiya S, Wang W, Carney E, Durbecq V et al (2008) A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clinical Cancer Res: An Official J Am Assoc Cancer Res 14(9):2601–2608. doi:10.1158/1078-0432
Breast Cancer Index by bioTheranostics. http://www.biotheranostics.com. Accessed May 2012
Acknowledgments
The authors are grateful to Ms Rebecca Johnston and Dr Ana Cristina Vargas for critical review and assistance with preparation of this manuscript. We would also like to acknowledge our funding agencies: The Australian National Health and Medical Research Council, The Qld Cancer Council, Pathology Queensland, The Queensland Health Pathology and Scientific Services Study, Education and Research Trust Fund (SERTF), The Royal Brisbane and Women’s Hospital and The University of Queensland.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Saunus, J.M., McCart-Reed, A., Momeny, M., Cummings, M., Lakhani, S.R. (2013). Breast Cancer Heterogeneity in Primary and Metastatic Disease. In: Ahmad, A. (eds) Breast Cancer Metastasis and Drug Resistance. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5647-6_5
Download citation
DOI: https://doi.org/10.1007/978-1-4614-5647-6_5
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-5646-9
Online ISBN: 978-1-4614-5647-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)